From surging raw material prices to looming tariffs on imported APIs, pharmaceutical buyers in 2025 are undergoing inflationary pressure from every corner.
The rising costs of brand-name drugs is largely driven by inflation in the prices of widely used existing drugs, according to a study published in the January issue of Health Affairs…